Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system

References

• Cancer Facts & Figures. 2017. American cancer society. [cited Jul 2018 21]. Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2017/cancer-facts-and-figures-2017.pdf
   Google Scholar
• Keytruda Drug Approval Package. Food and drug administration. October 2 2014. [cited 2018 Jul 21]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125514Orig1s000TOC.cfm
   Google Scholar
• OPDIVO Drug Approval Package. Food and drug administration. January 21 2015. [cited 2018 Jul 21]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125554Orig1s000TOC.cfm
   Google Scholar
• Keytruda Label. Food and drug administration. [ Updated June 2018; cited 2018 Sept 25]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125514s034lbl.pdf
   Google Scholar
• OPDIVO Label. Food and drug administration. [ Updated August, 2018; cited Sept, 2018]. Available from: https://www.accessdata.fda.gov/spl/data/f8d6b00a-7b1d-4303-8537-773b3482563a/f8d6b00a-7b1d-4303-8537-773b3482563a.xml
   Google Scholar
• Wahid M, Akhter N, Jawed A, et al. Pembrolizumab’s non-cross resistance mechanism of action successfully overthrown ipilimumab. Crit Rev Oncol Hematol. 2017;111:1–6.
   PubMedGoogle Scholar
• Liu RC, Consuegra G, Chou S, et al. Vitiligo-like depigmentation in oncology patients treated with immunotherapies for nonmelanoma metastatic cancers. Clin Exp Dermatol. 2019. DOI:10.1111/ced.13867
   Google Scholar
• Collins LK, Chapman MS, Carter JB, et al. Cutaneous adverse effects of the immune checkpoint inhibitors. Curr Probl Cancer. 2017;41(2):125–128.
   PubMed Web of Science ®Google Scholar
• Bulbul A. Vitiligoid hypopigmentation associated with pembrolizumab in metastatic head and neck cancer. Oxf Med Case Reports. 2019;2019(3).
   PubMedGoogle Scholar
• Voudouri D, Nikolaou V, Laschos K, et al. Anti-PD1/PDL1 induced psoriasis. Curr Probl Cancer. 2017;41(6):407–412.
   PubMed Web of Science ®Google Scholar
• Chujo S, Asahina A, Itoh Y. New onset of psoriasis during nivolumab treatment for lung cancer. J Dermatol. 2018;45(3):e55-e56.
   PubMed Web of Science ®Google Scholar
• Sugiura Y, Fujimoto H, Yamamoto M, et al. Psoriasis and psoriatic arthritis induced by nivolumab in a patient with advanced non-small-cell lung cancer. Gan To Kagaku Ryoho. 2017;44(9):787–789.
   PubMedGoogle Scholar
• Adler NR, Aung AK, Ergen EN, et al. Recent advances in the understanding of severe cutaneous adverse reactions. Br J Dermatol. 2017;177(5):1234–1247.
   PubMed Web of Science ®Google Scholar
• Schmidt E, Zillikens D. Pemphigoid diseases. Lancet. 2013;381(9863):320–332.
   PubMed Web of Science ®Google Scholar
• Vaillant L, Bernard P, Joly P, et al. Evaluation of clinical criteria for diagnosis of bullous pemphigoid. Arch Dermatol. 1998;134(9):1075–1080.
   PubMedGoogle Scholar
• Kridin K, Ludwig RJ. The growing incidence of bullous pemphigoid: overview and potential explanations. Front Med (Lausanne). 2018;5:220.
   PubMed Web of Science ®Google Scholar
• Brick KE, Weaver CH, Lohse CM, et al. Incidence and mortality rates of bullous pemphigoid in olmsted county, minnesota, over 6 decades. J Am Acad Dermatol. 2014;71(1):92–99.
   PubMed Web of Science ®Google Scholar
• Wojnarowska F, Kirtschig G, Highet AS, et al. Guidelines for the management of bullous pemphigoid. Br J Dermatol. 2002;147(2):214–221.
   PubMed Web of Science ®Google Scholar
• Ali AK, Watson DE. Pharmacovigilance assessment of immune-mediated reactions reported for checkpoint inhibitor cancer immunotherapies. Pharmacotherapy. 2017;37(11):1383–1390.
   PubMed Web of Science ®Google Scholar
• Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMAOncol. 2018;4(12):1721–1728.
   Google Scholar
• Oshima Y, Tanimoto T, Yuji K, et al. EGFR-TKI-associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer. JAMAOncol. 2018;4(8):1112–1115.
   Google Scholar
• FDA’s Adverse Event Reporting System (FAERS). Food and drug administration. [Updated Jun 4, 2018; cited Jul 21 2018]. Available from: https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/default.htm
   Google Scholar
• MedDRA. Medical dictionary for regulatory activities (MedDRA). [cited 2019 May 6] Available from: https://www.meddra.org/.
   Google Scholar
• Tamura T, Sakaeda T, Kadoyama K, et al. Omeprazole and esomeprazole-associated hypomagnesaemia: data mining of the public version of the fda adverse event reporting system. Int J Med Sci. 2012;9(5):322–326.
   PubMed Web of Science ®Google Scholar
• Bate A, Lindquist M, Edwards IR, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998;54(4):315–321.
   PubMed Web of Science ®Google Scholar
• Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10(6):483–486.
   PubMed Web of Science ®Google Scholar
• Van Puijenbroek EP, van Grootheest K, Diemont WL, et al. Determinants of signal selection in a spontaneous reporting system for adverse drug reactions. Br J Clin Pharmacol. 2001;52(5):579–586.
   PubMed Web of Science ®Google Scholar
• US National Library of medicine, national institutes of health. PubMed [database]. [cited 2019 May 6]. Available from: http://www.ncbi.nlm.nih.gov/pubmed
   Google Scholar
• Jour G, Glitza IC, Ellis RM, et al. Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions. J CutanPathol. 2016;43:688–696.
   Web of Science ®Google Scholar
• Thomsen K, Diernaes J, Øllegaard TH, et al. Bullous pemphigoid as an adverse reaction to pembrolizumab: two case reports. Case Rep Dermatol. 2018;10(2):154–157.
   PubMed Web of Science ®Google Scholar
• Beck KM, Dong J, Geskin LJ, et al. Disease stabilization with pembrolizumab for metastatic acral melanoma in the setting of autoimmune bullous pemphigoid. J Immunother Cancer. 2016;4:20.
   PubMed Web of Science ®Google Scholar
• Ridpath AV, Rzepka PV, Shearer SM, et al. Novel use of combination therapeutic plasma exchange and rituximab in the treatment of nivolumab-induced bullous pemphigoid. Int J Dermatol. 2018;57(11):1372–1374.
   PubMed Web of Science ®Google Scholar
• Sowerby L, Dewan AK, Granter S, et al. Rituximab treatment of nivolumab-induced bullous pemphigoid. JAMA Dermatol. 2017;153(6):603–605.
   PubMed Web of Science ®Google Scholar
• Lopez AT, Khanna T, Antonov V, et al. A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors. Int J Dermatol. 2018;57(6):664–669.
   PubMed Web of Science ®Google Scholar
• Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245.
   PubMed Web of Science ®Google Scholar
• Curry JL, Tetzlaff MT, Nagarajan P, et al. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. J Cutan Pathol. 2017;44(2):158–176.
   PubMed Web of Science ®Google Scholar
• Amber KT, Valdebran M, Lu Y, et al. Localized pretibial bullous pemphigoid arising in a patient on pembrolizumab for metastatic melanoma. J Dtsch Dermatol Ges. 2018;16(2):196–198.
   Web of Science ®Google Scholar
• Anastasopoulou A, Papaxoinis G, Diamantopoulos P, et al. Bullous pemphigoid-like skin lesions and overt eosinophilia in a patient with melanoma treated with nivolumab: case report and review of the literature. J Immunother. 2018;41(3):164–167.
   PubMed Web of Science ®Google Scholar
• Garje R, Chau JJ, Chung J, et al. Acute flare of bullous pemphigus with pembrolizumab used for treatment of metastatic urothelial cancer. J Immunother. 2018;41(1):42–44.
   PubMed Web of Science ®Google Scholar
• Haug V, Behle V, Benoit S, et al. Pembrolizumab-associated mucous membrane pemphigoid in a patient with merkel cell carcinoma. Br J Dermatol. 2018;179(4):993–994.
   PubMed Web of Science ®Google Scholar
• Zumelzu C, Alexandre M, Le Roux C, et al. Mucous membrane pemphigoid, bullous pemphigoid, and anti-programmed death-1/programmed death-ligand 1: a case report of an elderly woman with mucous membrane pemphigoid developing after pembrolizumab therapy for metastatic melanoma and review of the literature. Front Med (Lausanne). 2018;5:268.
   PubMed Web of Science ®Google Scholar
• Sun CW, Grossman SK, Aphale A, et al. Pembrolizumab-induced bullous pemphigoid. JAAD Case Rep. 2019;5(4):362–364.
   PubMedGoogle Scholar
• Honigman AD, Lai F, Elakis J, et al. Pembrolizumab-induced sarcoid granulomatous panniculitis and bullous pemphigoid in a single patient. Clin Case Rep. 2019;7(4):773–775.
   PubMed Web of Science ®Google Scholar
• Adachi E, Honda T, Nonoyama S, et al. Severe bullous pemphigoid in a metastatic lung cancer patient treated with pembrolizumab. J Dermatol. 2019. DOI:10.1111/1346-8138.14813
   Google Scholar
• Grimaux X, Delva R, Jadaud E, et al. Nivolumab-induced bullous pemphigoid after radiotherapy and abscopal effect. Australas J Dermatol. 2018. DOI:10.1111/ajd.12987
   PubMedGoogle Scholar
• Panariello L, Fattore D, Annunziata MC, et al. Bullous pemphigoid and nivolumab: dermatologic management to support and continue oncologic therapy. Eur J Cancer. 2018;103:284–286.
   PubMed Web of Science ®Google Scholar
• Williams HC, Wojnarowska F, Kirtschig G, et al. Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. Lancet. 2017;389(10079):1630–1638.
   PubMed Web of Science ®Google Scholar
• Bandino JP, Perry DM, Clarke CE, et al. Two cases of anti-programmed cell death 1-associated bullous pemphigoid-like disease and eruptive keratoacanthomas featuring combined histopathology. J Eur Acad Dermatol Venereol. 2017;31(8):e378–e380.
   PubMed Web of Science ®Google Scholar
• Siegel J, Totonchy M, Damsky W, et al. Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy. J Am Acad Dermatol. 2018;79(6):1081–1088.
   PubMed Web of Science ®Google Scholar
• Márquez-Rodas I, Cerezuela P, Soria A, et al. Immune checkpoint inhibitors: therapeutic advances in melanoma. Ann Transl Med. 2015;3(18):267.
   PubMed Web of Science ®Google Scholar
• Liu Y, Li L, Xia Y. BP180 is critical in the autoimmunity of bullous pemphigoid. Front Immunol. 2017;8:1752.
   PubMed Web of Science ®Google Scholar
• Goletz S, Zillikens D, Schmidt E. Structural proteins of the dermal-epidermal junction targeted by autoantibodies in pemphigoid diseases. ExpDermatol. 2017;26(12):1154–1162.
   Web of Science ®Google Scholar
• Chen CB, Wu MY, Ng CY, et al. Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies. Cancer Manag Res. 2018;10:1259–1273.
   PubMed Web of Science ®Google Scholar
• Xu C, Chen YP, Du XJ, et al. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. Bmj. 2018;363:k4226.
   PubMed Web of Science ®Google Scholar
• Aggarwal N. Local anesthetics systemic toxicity association with exparel (bupivacaine liposome)- a pharmacovigilance evaluation. Expert Opin Drug Saf. 2018;17(6):581–587.
   PubMed Web of Science ®Google Scholar
• Aggarwal N. Drug-induced subacute cutaneous lupus erythematosus associated with proton pump inhibitors. Drugs Real World Outcomes. 2016;3(2):145–154.
   PubMedGoogle Scholar
• Michel C, Scosyrev E, Petrin M, et al. can disproportionality analysis of post-marketing case reports be used for comparison of drug safety profiles? Clin Drug Investig. 2017;37(5):415–422.
   PubMed Web of Science ®Google Scholar